NKGen Biotech Selected As Stalking Horse Bidder For NKMax; NKGen Proposal Included Up To $18M In Committed Funding.
NKGen Biotech Selected As Stalking Horse Bidder For NKMax; NKGen Proposal Included Up To $18M In Committed Funding.
- Upon closing, the transaction would secure global IP rights for NKGen.
- NKGen and its partners can begin to commercialize troculeucel in Korea, Japan and other markets where natural-killer ("NK") cell therapy is already legal.
- NKGen proposal included up to $18 million in committed funding.
- Closing expected in 1Q 2025.
- 交易完成後，該交易將確保納斯達克的全球知識產權。
- NKGen及其合作伙伴可以在韓國、日本和其他自然殺傷（"NK"）細胞療法已經合法的市場開始商業化troCuleucel。
- NKGen的提案中包括高達1800萬美元的承諾資金。
- 預計於2025年第一季度完成交易。
SANTA ANA, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer cell therapeutics, today announced it has been selected as the preferred stalking horse bidder for NKMax Co., Ltd. ("NKMax") in NKMax's court-managed rehabilitation process in South Korea. NKMax filed for rehabilitation in South Korea, roughly similar to Chapter 11 in the US, on April 18, 2024, and currently holds an approximate 25% equity interest in NKGen. NKGen's proposal included up to $18 million in committed funding from a third-party investor. As is typical in US bankruptcies, there will now be a public offering process, with NKGen having final right of first refusal on any other qualified offers, with the final decision and ultimate rehabilitation plan approved by NKMax's creditors and the court expected in February 2025 and closing thereafter (the "Acquisition"). NKGen and its financing partners expect to hold a majority of the equity of NKMax at closing.
加州聖安娜，2024年12月02日（全球新聞社）--納斯達克生物技術公司（NASDAQ:NKGN）（"NKGen"或"公司"），一家專注於開發和商業化創新的自體和異體自然殺傷細胞治療藥物的臨床階段生物技術公司，今天宣佈已被選爲NKMax Co., Ltd.（"NKMax"）在南韓的法院管理的康復過程中的優先拍賣競標人。 NKMax於2024年4月18日在韓國申請破產重整，與美國的第11章差不多，在NKGen擁有大約25%的股權。 NKGen的提案中包括來自第三方投資者高達1800萬美元的承諾資金。在美國破產案件中很typical，現在將有一個公開招標過程，NKGen有權拒絕其他任何合格報價，最終決定和最終康復計劃預計將於2025年2月獲得NKMax的債權人和法院批准，之後進行交易（"收購"）。 NKGen及其融資夥伴預計在交易完成時持有NKMax的大部分股權。
譯文內容由第三人軟體翻譯。
